Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of H7N9 Vaccine Delivered by Microarray Patch in Healthy Adults
NCT06417853Phase 1Completed
- Sponsor
- Vaxxas
- Start
- Jul 2024
- Primary completion
- Jan 2026
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines, Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised trial in avian influenza A H7N9 virus infection (H7N9) (8 arms), sponsored by Vaxxas. Primary endpoints: Incidence, severity and duration of solicited systemic adverse reactions, Incidence, severity and duration of local adverse reactions and 8 more. Started Jul 2024; status: completed.
02
Conditions
avian influenza A H7N9 virus infection (H7N9)
Beyond the preview
Go deeper on NCT06417853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06417853.